Objective To study the biological behavior of silicon nanoparticles in penetrating the blood-prostate barrier. Methods Silicon nanoparticles were prepared by means of chemical procedures.The silicon nanoparticles were added into HT1080 cells and cultured for 48 h to observe the distribution of nanoparticles in the cells.The nanosuspension at gradient concentration (0.005,0.010,0.015,0.020,0.025 ml/g)was injected into 100 mice (20 mice of each group) intraperitoneally or via tail vein to study the distribution of nanoparticles in the prostate.Additional 20 mice served as controls.The mortality and toxic reaction at 2 weeks after injection were also recorded. Results Electronic microscopy confirmed the penetration of silicon nanoparticles into HT1080 cells,the prostate gland and interstitial tissue,with intracellular ultrastructure intact.There was no significant difference in body weight,diet,defecation and activities among the 5 treatment groups and control group. Conclusions Silicon nanoparticles can overcome the obstruction of drug transportation by blood-prostate barrier or other biomembranes and thus may be promising as a drug carrier in treatment of prostate diseases.

Objective To explore the role and clinical significance of GSTM 3 ( glutathione S-trans-ferase mu 3) expression in prostate cancer (PCa). Methods We had used the two-dimensional fluores-cence difference gel electrophoresis ( 2D-DIGE) and mass spectral analysis to further verify the microarray data of mRNA expression profiling discovered .GSTM3 mRNA level was detected by Rael-time Quantitative PCR ( RT-QPCR) in 28 pairs of prostate cancer tissue and benign tissue .The relationship of GSTM 3 level with the serum PSA level and the clinical feature of PCa were analyzed . Results In 2D-DIGE study, we found that the expression of GSTM 3 protein in adjacent tissues was significantly higher than that in PCa tis-sues (P<0.05).RT-QPCR results showed that GSTM3 in adjacent tissues (8.12±0.51) was significantly higher than that in PCa tissues (7.18±0.54) (P<0.05).There was no significant difference of GSTM3 ex-pression in different serum PSA packets ( P>0.05) and prostate cancer clinical pathological parameters ( P>0.05). Conclusions GSTM3 expression is down-regulated in PCa tissues, and we may identify PCa by detecting the GSTM 3 expression .

[Objective] To investigate the effect of sporoderm-broken spores of Ganoderma Lucidum in the treatment of partial androgen deficiency of the aging male (PADAM) . [Methods] Random number table was used for the division of 138 PADAM cases. Sporoderm-broken Ganoderma Lucidum spores capsules were given orally to group A (n=80) and placebo to group B (n=58). The treatment course lasted 3 weeks. Self-scoring of physical ability, vasomotoricity, mental psychological state and sexual function was used to evaluate the therapeutic effect. Meanwhile, blood contents of testosterone (T), erythrocyte superoxide dismutase (SOD) and malondialdehyde (MDA) were determined and adverse reaction was observed. [Results] After a 3-week treatment, the scores of physical ability, vasomotoricity, mental psychological state and sexual function were decreased in group A (P 0.05) and the difference was significant between the two groups (P

Objective: To summarize the clinical effects of Shuxuening Injection on diseases and evaluate the quality of evidence to provide reference for the clinical application of Shuxuening Injection. Methods: Journal articles and conference papers were retrieved from the databases CNKI, Wanfang, VIP, CBM, EMbase, Pubmed and Cochrane with thematic word"Shuxuening"in Chinese and English, then all forms of clinical studies were screened and the disease types and frequency were analyzed, the dominant disease types of Shuxuening Injection were identified. Futhermore, RCT was extracted, and the literature quality was graded using the cochrane manual recommendation method, and its effectiveness and safety were evaluated. Results: All clinical research results show that Shuxuening Injection to treat disease with as many as 74 kinds of varieties, mainly circulation system disease and neural system disease, followed by endocrine disease, respiratory disease, scattered remaining research in ten other system diseases. These researches appeared with the highest frequency of the three diseases were cerebral infarction and its aftermath, angina pectoris and coronary heart disease, diabetes mellitus and its complication. A total of 337 RCT articles were included, all of which were of poor quality. In general, the efficiency of Shuxuening Injection treatment group was significantly higher than that of the control group, with a total efficiency of 84.48％. There were 21.96％ references to adverse reactions, but all of them were minor adverse reactions, such as pruritus, which generally got better by itself or after treatment. Conclusion:Shuxuening Injection has a wide range of clinical application and remarkable effect, especially for the ischemic diseases of cardiovascular and cerebrovascular diseases with good efficacy, less adverse reactions and safety. However, the quality of evidence is generally poor, which needs further study.